219 related articles for article (PubMed ID: 18172301)
21. The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance.
Schittek B; Psenner K; Sauer B; Meier F; Iftner T; Garbe C
Int J Cancer; 2007 May; 120(10):2110-8. PubMed ID: 17266041
[TBL] [Abstract][Full Text] [Related]
22. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
[TBL] [Abstract][Full Text] [Related]
23. Surmounting chemoresistance by targeting the Y-box binding protein-1.
Inoue I; Matsumoto K; Yu Y; Bay BH
Anat Rec (Hoboken); 2012 Feb; 295(2):215-22. PubMed ID: 22190445
[TBL] [Abstract][Full Text] [Related]
24. YB-1 promotes transcription of cyclin D1 in human non-small-cell lung cancers.
Harada M; Kotake Y; Ohhata T; Kitagawa K; Niida H; Matsuura S; Funai K; Sugimura H; Suda T; Kitagawa M
Genes Cells; 2014 Jun; 19(6):504-16. PubMed ID: 24774443
[TBL] [Abstract][Full Text] [Related]
25. Effect of YB-1 on the regulation of micro RNA expression in drug-sensitive and drug-resistant gastric carcinoma cells.
Belian E; Kurucz R; Treue D; Lage H
Anticancer Res; 2010 Feb; 30(2):629-33. PubMed ID: 20332481
[TBL] [Abstract][Full Text] [Related]
26. Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.
Shiota M; Takeuchi A; Song Y; Yokomizo A; Kashiwagi E; Uchiumi T; Kuroiwa K; Tatsugami K; Fujimoto N; Oda Y; Naito S
Endocr Relat Cancer; 2011 Aug; 18(4):505-17. PubMed ID: 21652770
[TBL] [Abstract][Full Text] [Related]
27. Regulation of mRNA expression in drug-sensitive and drug-resistant gastric carcinoma cells is independent of YB-1 expression.
Kurucz R; Belian E; Treue D; Lage H
Anticancer Res; 2010 Feb; 30(2):693-8. PubMed ID: 20332492
[TBL] [Abstract][Full Text] [Related]
28. Y-box binding protein-1 (YB-1) promotes cell cycle progression through CDC6-dependent pathway in human cancer cells.
Basaki Y; Taguchi K; Izumi H; Murakami Y; Kubo T; Hosoi F; Watari K; Nakano K; Kawaguchi H; Ohno S; Kohno K; Ono M; Kuwano M
Eur J Cancer; 2010 Mar; 46(5):954-65. PubMed ID: 20079629
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of Twist-1 by NF-kappaB blocks cytotoxicity induced by chemotherapeutic drugs.
Pham CG; Bubici C; Zazzeroni F; Knabb JR; Papa S; Kuntzen C; Franzoso G
Mol Cell Biol; 2007 Jun; 27(11):3920-35. PubMed ID: 17403902
[TBL] [Abstract][Full Text] [Related]
30. Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer.
Yahata H; Kobayashi H; Kamura T; Amada S; Hirakawa T; Kohno K; Kuwano M; Nakano H
J Cancer Res Clin Oncol; 2002 Nov; 128(11):621-6. PubMed ID: 12458343
[TBL] [Abstract][Full Text] [Related]
31. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures.
Guay D; Evoy AA; Paquet E; Garand C; Bachvarova M; Bachvarov D; Lebel M
Int J Biochem Cell Biol; 2008; 40(11):2492-507. PubMed ID: 18571458
[TBL] [Abstract][Full Text] [Related]
32. Association of nuclear YB-1 localization with lung resistance-related protein and epidermal growth factor receptor expression in lung cancer.
Hyogotani A; Ito K; Yoshida K; Izumi H; Kohno K; Amano J
Clin Lung Cancer; 2012 Sep; 13(5):375-84. PubMed ID: 22284440
[TBL] [Abstract][Full Text] [Related]
33. Twist: a molecular target in cancer therapeutics.
Khan MA; Chen HC; Zhang D; Fu J
Tumour Biol; 2013 Oct; 34(5):2497-506. PubMed ID: 23873099
[TBL] [Abstract][Full Text] [Related]
34. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.
Shiota M; Zoubeidi A; Kumano M; Beraldi E; Naito S; Nelson CC; Sorensen PH; Gleave ME
Mol Cancer Res; 2011 Dec; 9(12):1755-66. PubMed ID: 21987172
[TBL] [Abstract][Full Text] [Related]
35. P300/CBP-associated factor regulates Y-box binding protein-1 expression and promotes cancer cell growth, cancer invasion and drug resistance.
Shiota M; Yokomizo A; Tada Y; Uchiumi T; Inokuchi J; Tatsugami K; Kuroiwa K; Yamamoto K; Seki N; Naito S
Cancer Sci; 2010 Aug; 101(8):1797-806. PubMed ID: 20491776
[TBL] [Abstract][Full Text] [Related]
36. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light.
Ohga T; Koike K; Ono M; Makino Y; Itagaki Y; Tanimoto M; Kuwano M; Kohno K
Cancer Res; 1996 Sep; 56(18):4224-8. PubMed ID: 8797596
[TBL] [Abstract][Full Text] [Related]
37. Suppression of Her2/neu expression through ILK inhibition is regulated by a pathway involving TWIST and YB-1.
Kalra J; Sutherland BW; Stratford AL; Dragowska W; Gelmon KA; Dedhar S; Dunn SE; Bally MB
Oncogene; 2010 Dec; 29(48):6343-56. PubMed ID: 20838384
[TBL] [Abstract][Full Text] [Related]
38. Twist promotes invasion and cisplatin resistance in pancreatic cancer cells through growth differentiation factor 15.
Ji H; Lu HW; Li YM; Lu L; Wang JL; Zhang YF; Shang H
Mol Med Rep; 2015 Sep; 12(3):3841-3848. PubMed ID: 26018318
[TBL] [Abstract][Full Text] [Related]
39. Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-κB signaling pathway in human neuroblastoma SH-SY5Y cells.
Wang H; Sun R; Chi Z; Li S; Hao L
Mol Cell Biochem; 2017 Sep; 433(1-2):1-12. PubMed ID: 28382490
[TBL] [Abstract][Full Text] [Related]
40. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
